SPDR S&P Pharmaceuticals ETF
XPH
XPH
60 hedge funds and large institutions have $84.3M invested in SPDR S&P Pharmaceuticals ETF in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
58% less call options, than puts
Call options by funds: $366K | Put options by funds: $878K
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Holders
60
Holding in Top 10
–
Calls
$366K
Puts
$878K
Top Buyers
| 1 | +$2.07M | |
| 2 | +$1.82M | |
| 3 | +$805K | |
| 4 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$683K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$421K |
Top Sellers
| 1 | -$20.4M | |
| 2 | -$2.35M | |
| 3 | -$1.46M | |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.37M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.22M |